Suppr超能文献

在人急性髓性白血病细胞中抑制雷帕霉素哺乳动物靶标具有多种取决于体外环境应激的效应。

Inhibition of Mammalian target of rapamycin in human acute myeloid leukemia cells has diverse effects that depend on the environmental in vitro stress.

作者信息

Ryningen Anita, Reikvam Håkon, Nepstad Ina, Paulsen Rye Kristin, Bruserud Oystein

机构信息

Division of Hematology, Institute of Medicine, University of Bergen, N-5021 Bergen, Norway ; Department of Medicine, Haukeland University Hospital, N-5021 Bergen, Norway.

出版信息

Bone Marrow Res. 2012;2012:329061. doi: 10.1155/2012/329061. Epub 2012 Oct 2.

Abstract

Effects of the mTOR inhibitor rapamycin were characterized on in vitro cultured primary human acute myeloid leukemia (AML) cells and five AML cell lines. Constitutive mTOR activation seemed to be a general characteristic of primary AML cells. Increased cellular stress induced by serum deprivation increased both mTOR signaling, lysosomal acidity, and in vitro apoptosis, where lysosomal acidity/apoptosis were independent of increased mTOR signaling. Rapamycin had antiproliferative and proapoptotic effects only for a subset of patients. Proapoptotic effect was detected for AML cell lines only in the presence of serum. Combination of rapamycin with valproic acid, all-trans retinoic acid (ATRA), and NF-κB inhibitors showed no interference with constitutive mTOR activation and mTOR inhibitory effect of rapamycin and no additional proapoptotic effect compared to rapamycin alone. In contrast, dual inhibition of the PI3K-Akt-mTOR pathway by rapamycin plus a PI3K inhibitor induced new functional effects that did not simply reflect a summary of single drug effects. To conclude, (i) pharmacological characterization of PI3K-Akt-mTOR inhibitors requires carefully standardized experimental models, (ii) rapamycin effects differ between patients, and (iii) combined targeting of different steps in this pathway should be further investigated whereas combination of rapamycin with valproic acid, ATRA, or NF-κB inhibitors seems less promising.

摘要

在体外培养的原代人急性髓系白血病(AML)细胞和五种AML细胞系中对mTOR抑制剂雷帕霉素的作用进行了表征。组成型mTOR激活似乎是原代AML细胞的一个普遍特征。血清剥夺诱导的细胞应激增加会同时增加mTOR信号传导、溶酶体酸度和体外凋亡,其中溶酶体酸度/凋亡与mTOR信号传导增加无关。雷帕霉素仅对一部分患者具有抗增殖和促凋亡作用。仅在有血清存在的情况下才检测到雷帕霉素对AML细胞系有促凋亡作用。雷帕霉素与丙戊酸、全反式维甲酸(ATRA)和NF-κB抑制剂联合使用时,未显示出对组成型mTOR激活和雷帕霉素的mTOR抑制作用有干扰,与单独使用雷帕霉素相比也没有额外的促凋亡作用。相比之下,雷帕霉素加PI3K抑制剂对PI3K-Akt-mTOR途径的双重抑制诱导了新的功能效应,这并非简单地反映单一药物效应的总和。总之,(i)PI3K-Akt-mTOR抑制剂的药理学表征需要仔细标准化的实验模型,(ii)雷帕霉素的作用在不同患者之间存在差异,(iii)该途径中不同步骤的联合靶向应进一步研究,而雷帕霉素与丙戊酸、ATRA或NF-κB抑制剂联合使用似乎前景不太乐观。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/75a4/3467767/8851fcb4ece7/BMR2012-329061.001.jpg

相似文献

6
The PI3K-Akt-mTOR Signaling Pathway in Human Acute Myeloid Leukemia (AML) Cells.
Int J Mol Sci. 2020 Apr 21;21(8):2907. doi: 10.3390/ijms21082907.
10
Inhibition of mTOR kinase as a therapeutic target for acute myeloid leukemia.
Expert Opin Ther Targets. 2017 Jul;21(7):705-714. doi: 10.1080/14728222.2017.1333600. Epub 2017 Jun 9.

本文引用的文献

1
Inhibition of the mTORC2 and chaperone pathways to treat leukemia.
Blood. 2012 Jun 21;119(25):6080-8. doi: 10.1182/blood-2011-12-399519. Epub 2012 May 7.
4
Acute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management.
Am J Hematol. 2012 Jan;87(1):89-99. doi: 10.1002/ajh.22246.
6
Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.
J Clin Oncol. 2012 Jan 20;30(3):282-90. doi: 10.1200/JCO.2011.36.1360. Epub 2011 Dec 12.
9
New phosphatidylinositol 3-kinase inhibitors for cancer.
Expert Opin Investig Drugs. 2011 Apr;20(4):507-18. doi: 10.1517/13543784.2011.562192.
10
Current and future directions in mammalian target of rapamycin inhibitors development.
Expert Opin Investig Drugs. 2011 Mar;20(3):381-94. doi: 10.1517/13543784.2011.541154. Epub 2011 Feb 8.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验